Inovio Pharmaceuticals Inc. (INO) Dividend Safety Gauge & 10-Year DRIP Compounder

Per the Roarable RQD rating, INO scores 34 out of 100 and carries a letter grade of E, with the verdict "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars are:

• Fundamental Cash Engine: 6 / 20. Per the RQD rating, ROIC is -35% and FCF yield is 0%. Per the market data section, operating margin and net margin are both -60%, and gross margin is 0%. The cash engine is not generating returns on invested capital, which means the equity case rests on future events rather than current economics.
• Whale / 13F Flow: 12 / 20. The RQD rating describes institutional accumulation and options positioning as a partial positive. No holder-level detail is supplied in the source data, so the composition of this flow cannot be verified here.
• Insider Conviction: 3 / 20. The RQD rating assigns a low score to SEC Form 4 and Congressional PTR flow. This is the weakest pillar relative to its weight and signals limited insider alignment with the stock.
• Macro Regime Fit: 8 / 20. Per the RQD rating and market data, beta is 1.0 and the stock is sector-sensitive. The rating does not indicate a macro tailwind.
• Forensic Balance Sheet: 5 / 20. Per the RQD rating, Altman Z is 2.5, Piotroski F is 2/9, and Debt/Equity is 0.5. Taken together these point to weak financial health under forensic screening.

For a prospective investor evaluating the stock today, the rating's composition matters more than the headline score. The highest-scoring pillar (whale flow) is the only one above the midpoint, while the cash engine, insider conviction, and forensic balance sheet all sit in the bottom third. Upside in this framework depends on a re-rating of the cash engine, which per the market data is currently at 0% FCF yield, meaning valuation is not supported by reported cash generation. The stock's price of 0.6 with a market cap of $79.8M and a 52-week range of $0.56 to $2.72 reflects a steep decline already in progress, with the change_pct at -22.08%. Any investor weighing the RQD verdict should recognize that a low score here is a structural assessment, not a timing signal.

Inovio Pharmaceuticals Inc. is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Pharmaceutical Preparations industry, per the company profile. The profile identifies the company's market capitalization as $0.1B. Customers, products, and revenue model are not described in the source data. Revenue is reported as $0.1M for FY 2025, per the SEC financials. The recent news wire references an FDA approval for a treatment for a rare throat disease, which is cited as a catalyst, but product-level commercial detail is not available in source data.

Per the SEC financials, revenue declined from $0.8M in FY 2023 to $0.1M in FY 2025, while operating losses narrowed from $-143.9M to $-86.8M over the same span. Per the market data, operating margin and net margin are each -60% and ROIC is -35%. Per the RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 2/9, with Debt/Equity at 0.5. Cash declined from $65.8M in FY 2024 to $44.3M in FY 2025. Debt is not available in source data for any period.

Per the recent news and catalysts section, the most recent headlines include:

• A Reuters report, tagged CATALYST, describing an FDA approval for a treatment for a rare throat disease, with the headline noting shares surged.
• A GuruFocus report, tagged CATALYST, reporting a 224% share surge after FDA approval of Voceryq for RRP.
• Several YELLOW-tagged market wire items from Yahoo! Finance Canada, Yahoo Finance UK, StockInvest.us, and Moomoo covering market action and institutional positioning, with no specific fundamental content beyond their summaries.

Risk watch items: the price decline of -22.08% and the 52-week low of $0.56 sit against the catalyst headlines, and the source data does not reconcile the timing of the surge against the current price. The butterfly supply-chain graph reports no supply chain and no proprietary signals, so no additional signal overlay is available.

Per the Butterfly Supply-Chain Graph, the supply chain is recorded as NONE, with no butterfly links and no proprietary signals. Upstream suppliers, downstream customers, and sector correlations beyond the Health Care sector classification are not available in source data. The main second-order watch item is the dependence of the equity case on the FDA-related catalysts cited in the news section: if those catalysts do not translate into revenue, the cash engine reflected in the RQD rating and the FY 2025 FCF of $-88.9M would remain the governing constraint.

• What is the company's cash runway given FY 2025 cash of $44.3M against FY 2025 FCF of $-88.9M?
• What is the debt balance across periods, since debt is reported as N/A throughout the source data?
• What is the revenue composition behind the $0.1M FY 2025 figure, and how does it relate to the cited FDA approval?
• Why does the price sit at $0.6 after catalyst headlines describing a surge, and what is the timing of that move relative to the data date?
• What are the constituents of the institutional and options flow that underpin the 12 / 20 whale pillar?